Semaglutide and Asthma: Could Weight Loss Drugs Reduce Asthma Attacks?
A new study has raised an interesting possibility for people living with asthma and chronic obstructive pulmonary disease (COPD): medications containing semaglutide may be associated with fewer respiratory flare-ups.
Semaglutide is best known as the active ingredient in medicines such as Ozempic and Wegovy. These drugs belong to a class known as GLP-1 receptor agonists and are widely used to manage type 2 diabetes and obesity.
Researchers investigating real-world medical records have now found that people taking GLP-1 medicines appeared to experience fewer asthma attacks and COPD exacerbations. The association was particularly noticeable among people using semaglutide.
However, experts stress that the findings do not mean semaglutide should currently be prescribed as an asthma treatment. More research, including clinical trials, is needed before doctors can determine whether the drug directly improves respiratory health.
What Did the New Study Find?
Researchers from Imperial College London examined health records involving tens of thousands of people who had started treatment with GLP-1 receptor agonists.
The study looked at whether these medications were associated with changes in acute respiratory events among people with asthma or COPD.
The results suggested that semaglutide was linked with a substantial reduction in asthma attacks. Researchers reported that asthma attacks were reduced by almost 40% among people taking semaglutide.
A smaller reduction was also observed among people with COPD, with flare-ups falling by around 20%.
The apparent benefit was particularly noticeable in people whose asthma was more pronounced. Researchers also reported that the relationship between GLP-1 treatment and fewer respiratory exacerbations appeared stronger at higher doses.
It is important to remember that these figures describe an association observed in health records. They do not establish that semaglutide directly caused the reduction in attacks.
Why Could Semaglutide Affect Asthma?
Semaglutide primarily works by mimicking a hormone called glucagon-like peptide-1, or GLP-1. This helps regulate blood sugar, slows digestion and can reduce appetite, which contributes to weight loss.
While its main uses are metabolic, scientists have become increasingly interested in the wider effects of GLP-1 medicines.
Obesity and respiratory disease can be closely connected. Excess body weight can increase inflammation, affect breathing mechanics and make some respiratory conditions more difficult to manage.
Semaglutide may also have effects related to inflammation and metabolic health. Previous research has suggested that GLP-1 receptor agonists could have anti-inflammatory properties, although the exact mechanisms behind any potential respiratory benefits remain unclear.
There is therefore a possibility that improvements in metabolic health, weight, inflammation or several factors combined could contribute to better respiratory outcomes.
At this stage, however, researchers cannot say exactly why people taking semaglutide experienced fewer asthma attacks.
Does Semaglutide Treat Asthma?
No. Semaglutide is not currently an established treatment for asthma.
This distinction is important.
People with asthma should continue following their prescribed treatment plan, which may include inhaled corticosteroids, bronchodilators or other medicines recommended by their healthcare professional.
The new research is observational and based on real-world health records. Although such studies can identify potentially important patterns, they cannot prove cause and effect in the same way as a properly designed randomised clinical trial.
For example, people taking semaglutide may differ from people who are not taking it in several ways. They may have different health conditions, healthcare habits, levels of obesity or diabetes, or access to medical treatment.
Researchers therefore need controlled trials to establish whether semaglutide itself can reduce asthma attacks.
What About COPD?
The study also found a potential connection between semaglutide and fewer COPD flare-ups.
COPD is a long-term lung condition that can cause breathlessness, coughing and recurring exacerbations. These flare-ups can significantly affect quality of life and may sometimes require hospital treatment.
The reported reduction in COPD exacerbations was smaller than the reduction seen for asthma, at approximately 20%.
That finding is nevertheless potentially important because COPD treatment remains an area where researchers are looking for additional approaches to reduce exacerbations.
As with asthma, semaglutide should not currently be viewed as a replacement for established COPD treatment.
Why Weight Loss May Matter for Respiratory Health
One possible explanation for the findings is the relationship between obesity and lung health.
Carrying excess weight can place additional pressure on the chest and abdomen, potentially making breathing more difficult. Obesity can also be associated with systemic inflammation and other metabolic changes.
For someone who has both obesity and asthma, losing weight may improve several aspects of health simultaneously.
Weight reduction can potentially make physical activity easier, improve metabolic health and reduce some of the factors that contribute to breathing difficulties.
This makes the relationship between weight management and asthma particularly interesting. However, it does not mean that every person with asthma needs to lose weight, nor does it establish that semaglutide directly prevents asthma attacks.
What Do Experts Say?
Researchers involved in the study have described the findings as encouraging but have warned against changing clinical practice based on the results alone.
Respiratory experts have similarly highlighted the importance of studying metabolic health alongside lung health.
The findings could encourage researchers to include respiratory outcomes in future clinical trials of GLP-1 medicines.
This could help answer several important questions. Do GLP-1 medicines directly reduce asthma attacks? Is the effect primarily related to weight loss? Could these medicines influence airway inflammation? And do different GLP-1 drugs have different effects on respiratory conditions?
Further research will be needed to answer these questions.
Our Analysis
The most interesting aspect of this research is that it potentially connects two areas of medicine that are often considered separately: metabolic health and respiratory health.
GLP-1 medicines have transformed the treatment landscape for obesity and type 2 diabetes. Their effects may extend beyond blood sugar control and weight reduction, but researchers are still working out exactly what those wider effects mean.
The reported reduction in asthma attacks is significant enough to deserve further investigation, particularly because asthma can be affected by obesity and inflammation.
However, it would be premature to describe semaglutide as an asthma medication.
The study provides evidence of an association rather than definitive proof of a treatment effect. This distinction is particularly important when interpreting health headlines because observational research can sometimes produce results that do not translate into clinical trials.
For now, the strongest conclusion is that semaglutide and respiratory health appear to have a potentially important relationship that deserves more research.
If future clinical trials confirm that semaglutide can reduce asthma or COPD exacerbations, it could eventually influence how doctors think about treating patients who have both respiratory and metabolic conditions.
What Should Patients Do?
People currently taking semaglutide for obesity or type 2 diabetes should not change their medication because of this study.
Likewise, people with asthma or COPD should not begin taking a GLP-1 medicine specifically to prevent respiratory attacks unless it has been prescribed for an approved indication by a qualified healthcare professional.
Anyone experiencing worsening asthma symptoms, increasing breathlessness, frequent coughing or repeated flare-ups should speak to their doctor or respiratory specialist.
Asthma treatment should always be tailored to the individual, and prescribed medicines should not be stopped or replaced without medical advice.
The Bottom Line
Early research suggests that semaglutide may be associated with fewer asthma attacks and COPD exacerbations, with the strongest association reported among people with asthma.
The findings are promising, particularly given the growing understanding of the links between obesity, inflammation, metabolic health and respiratory disease.
But this is not yet proof that semaglutide can treat or prevent asthma.
More rigorous clinical trials are needed to establish whether GLP-1 medicines genuinely provide respiratory benefits, which patients might benefit most and whether the effects are caused by weight loss, metabolic improvements, anti-inflammatory activity or another mechanism.
For now, semaglutide remains primarily a treatment for approved metabolic conditions, rather than a therapy for asthma or COPD.
Sources
- European Respiratory Society Congress, 2026. Research presented at the congress examined real-world health records to investigate whether GLP-1 receptor agonists were associated with fewer asthma attacks and COPD exacerbations.
- Imperial College London, National Heart and Lung Institute. Research led by Professor Chloe Bloom examining the relationship between GLP-1 receptor agonists and respiratory outcomes in people with asthma and COPD.
- Asthma + Lung UK. Expert commentary on emerging research into GLP-1 medicines, asthma and COPD, including the potential relationship between metabolic health and respiratory disease.
Disclaimer
This article is for general informational and educational purposes only. It is not intended to provide medical advice, diagnosis or treatment. The information discussed is based on research findings and publicly reported expert commentary and should not be used as a substitute for advice from a qualified healthcare professional.